Press Release :
Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9
VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial with PRO 140 (humanized CCR5 monoclonal antibody) in heavily treatment-experienced HIV-1 patients will be presented in a Late-Breaker Abstract poster session at ASM Microbe on Saturday, June 9, in Atlanta. The trial results detail data from the one-week, single-dose, randomized, double-blind, placebo-controlled portion of the pivotal trial of PRO140 in combination with optimized background anti-retroviral therapy (ART).
Session 226: Late Breaker Abstract poster session
Title: “Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients”
Date: Saturday June 9
Time: 11:00 am - 1:00 pm ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Georgia World Congress Center
Control/Tracking Number: 2018-LB-7818-MICROBE
About PRO 140
PRO 140 belongs to a new class of HIV/AIDS therapeutics – viral-entry inhibitors – that is intended to protect healthy cells from viral infection. PRO 140 is a humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T cells by masking this required co-receptor, CCR5. Importantly, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity toward CCR5 but does have antagonist activity to CCL5, which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product by the FDA. The FDA also granted orphan drug designation to PRO 140 for the prevention of graft-versus-host disease (GvHD). The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
